Method of creating crystalline substances
Process for preparing a cocrystal of an active substance and a cocrystal former, the process involving precipitating the active substance and the cocrystal former together from solution or suspension, in the presence of a supercritical or near-critical fluid, in particular using a GAS, SAS, SEDS or SAS-EM process. The invention also provides a cocrystal prepared using such a process, and its use as a seed crystal in a subsequent process for precipitating a cocrystal of an active substance and a cocrystal former.
1. A process for preparing a cocrystal of an active substance and a cocrystal former, the process comprising precipitating the active substance and the cocrystal former together from solution or suspension, in the presence of a supercritical or near-critical fluid, wherein the cocrystal former is selected such that the cocrystal former and the active substance are bonded together through hydrogen bonds to form the cocrystal.
2. The process according to claim 1 , wherein the supercritical or near-critical fluid is carbon dioxide.
3. The process according to claim 1 , wherein the active substance and the cocrystal former are precipitated from supercritical or near-critical fluid solution or suspension by a rapid reduction in pressure.
4. The process according to claim 1 , wherein the active substance and the cocrystal former are precipitated from solution or suspension by a supercritical or near-critical fluid anti-solvent.
5. The process according to claim 1 , wherein the active substance and the cocrystal former are precipitated from solution or suspension using a GAS, SAS, SEDS or SAS-EM process.
6. The process according to claim 1 , wherein the active substance and the cocrystal former are dissolved or suspended in a solvent system which is subsequently contacted with a supercritical or near-critical fluid and wherein the mixture of (a) the solution or suspension of the active substance and cocrystal former and (b) the supercritical or near-critical fluid is itself supercritical or near-critical.
7. The process according to claim 1 , wherein the active substance and the cocrystal former are precipitated from separate solutions or suspensions.
8. The process according to claim 1 , wherein the active substance is a pharmaceutically active substance.
9. The process according to claim 1 , wherein the cocrystal former is selected from the group consisting of a pharmaceutically active substance and a pharmaceutically inert, pharmaceutically acceptable substance.
10. The process according to claim 1 , wherein the molar ratio of the active substance to the cocrystal former is substantially stoichiometric.
11. The process according to claim 10 , wherein the stoichiometric molar ratio of the active substance to the cocrystal former is selected from the group consisting of 1:1, 1:1.5, or 1:2.
12. The process according to claim 10 , wherein the stoichiometric molar ratio of the active substance to the cocrystal former is 1:3.
13. The process according to claim 10 , wherein the stoichiometric molar ratio of the cocrystal former to the active substance is selected from the group consisting of 1:1.5, 1:2, or 1:3.
14. The process according to claim 10 , wherein the molar ratio of the active substance to the cocrystal former is within 20% of the stoichiometric value.
15. The process according to claim 14 , wherein the molar ratio of the active substance to the cocrystal former is within 10% of the stoichiometric value.
16. A process for the preparation of a cocrystal of an active substance and a cocrystal former, the process comprising precipitating a cocrystal from a solution or suspension of an active substance and a cocrystal former in the presence of a cocrystal seed crystal prepared by a process according to claim 1 .
17. A process for modifying a physicochemical property of an active substance, the process comprising precipitating the active substance from solution or suspension, in the presence of a supercritical or near-critical fluid, together with a cocrystal former so as to form a cocrystal precipitate having a physicochemical property different from that of the active substance, wherein the cocrystal former is selected such that the cocrystal former and the active substance are bonded together through hydrogen bonds to form the cocrystal.
18. The process according to claim 17 , wherein the physicochemical property that is modified is selected from solubility, dissolution profile, bioavailability, dose response profile, stability, saltability, hygroscopicity, morphology, polymorphic form and purity and restricting polymorphic form diversity.
19. The process according to claim 17 , which is used to increase the crystallinity of the active substance.
20. A process for preparing a composition containing an active substance, the process comprising forming a cocrystal comprising the active substance and a cocrystal former by precipitating the active substance and the cocrystal former together from solution or suspension, in the presence of a supercritical or near-critical fluid, wherein the cocrystal former is selected such that the cocrystal former and the active substance are bonded together through hydrogen bonds to form the cocrystal.
21. The process according to claim 20 , wherein the composition is a pharmaceutical composition.
22. A cocrystal prepared using a process according to claim 1 .
23. A cocrystal prepared using a process according to claim 10 .
24. A cocrystal prepared using a process according to claim 16 .
25. A composition containing an active substance, the composition having been prepared using a process according to claim 20 .